Evans Blue

Sold as Evans Blue. Every FDA application for this active ingredient.

As of Nov 14, 2026, FDA lists 1 application for Evans Blue (sold as Evans Blue), with 0 new uses approved and 0 published complete response letters.

First approved: not available
Applications: 1
New uses approved: 0
Complete response letters: 0

Clinical Trials

1 open or ongoing study names this ingredient as an intervention, including as a comparator; newest first. See all

Study	Phase	Status	Posted
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid CancerThyroid Cancer · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1 / Phase 2	Not yet recruiting	May 28, 2025

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
—	Evans BlueNDA 8041	Parke Davis	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA